vimarsana.com
Home
Live Updates
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) : comparemela.com
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 -- Reneo...
Related Keywords
United States ,
Gregoryj Flesher ,
Danielle Spangler ,
Ematthew Purcell ,
Russo Partners ,
Reneo Pharmaceuticals Inc ,
Item Health Survey ,
Reneo Pharmaceuticals ,
Health Problem ,
Exchange Commission ,
Nasdaq ,
Short Form Fatigue ,
Modified Fatigue Impact Scale ,
Patient Global Impression ,
Brief Pain Inventory ,
Work Productivity ,
Activity Impairment Questionnaire ,
Specific Health Problem ,
Pedometer Step ,
Private Securities Litigation Reform Act ,
Markets ,
comparemela.com © 2020. All Rights Reserved.